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Abstract
Background: In class prediction problems using microarray data, gene selection is essential to
improve the prediction accuracy and to identify potential marker genes for a disease. Among
numerous existing methods for gene selection, support vector machine-based recursive feature
elimination (SVM-RFE) has become one of the leading methods and is being widely used. The
SVM-based approach performs gene selection using the weight vector of the hyperplane
constructed by the samples on the margin. However, the performance can be easily affected by
noise and outliers, when it is applied to noisy, small sample size microarray data.
Results: In this paper, we propose a recursive gene selection method using the discriminant
vector of the maximum margin criterion (MMC), which is a variant of classical linear discriminant
analysis (LDA). To overcome the computational drawback of classical LDA and the problem of
high dimensionality, we present efficient and stable algorithms for MMC-based RFE (MMC-RFE).
The MMC-RFE algorithms naturally extend to multi-class cases. The performance of MMC-RFE
was extensively compared with that of SVM-RFE using nine cancer microarray datasets, including
four multi-class datasets.
Conclusion: Our extensive comparison has demonstrated that for binary-class datasets MMC-
RFE tends to show intermediate performance between hard-margin SVM-RFE and SVM-RFE with
a properly chosen soft-margin parameter. Notably, MMC-RFE achieves significantly better
performance with a smaller number of genes than SVM-RFE for multi-class datasets. The results
suggest that MMC-RFE is less sensitive to noise and outliers due to the use of average margin,
and thus may be useful for biomarker discovery from noisy data.
Background
Microarray technology allows us to measure the expres-
sion levels of thousands of genes simultaneously. A vast
amount of data produced by microarrays pose a great
challenge on conventional data mining and machine
learning methods, because the number of genes often
exceeds tens of thousands, whereas the number of sam-
ples is at most a few hundred.
Along with clustering and classification of genes and/or
samples, gene selection is an important aspect of microar-
ray data analysis, and has been a central issue in recent
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years [1,2]. Specifically, gene selection is used to identify
genes most relevant to sample classification, for example,
those differentiate between normal and cancerous tissue
samples. Gene selection plays essential roles in classifica-
tion tasks. It improves the prediction accuracy of classifi-
ers by using only discriminative genes. It also saves
computational costs by reducing dimensionality. More
importantly, if it is possible to identify a small subset of
biologically relevant genes, it may provide insights into
understanding the underlying mechanism of a specific
biological phenomenon. Also, such information can be
useful for designing less expensive experiments by target-
ing only a handful of genes.
The most common gene selection approach is so-called
gene ranking. It is a univariate approach in the sense that
each gene is evaluated individually with respect to a cer-
tain criterion that represents class discrimination ability.
The criteria often used are e.g., t-statistics, the signal-to-
noise (S2N) ratio [3,4] and the between-group to within-
group (BW) ratio [5]. Although such gene ranking criteria
are simple to use, they ignore correlations or interactions
among genes, which may be essential to class discrimina-
tion and characterization.
Among existing gene selection methods, support vector
machine-based recursive feature elimination (SVM-RFE)
[6] has become one of the leading methods and is being
widely used. It is a multivariate approach, hence the cor-
relations among genes can be taken into account. Moreo-
ver, since the selection is based on an SVM classifier, a
subset of genes that yields high classification performance
can be identified. Recently, the successful application of
SVM-RFE has motivated the development of several SVM-
based gene selection methods [7-9]. The SVM-based
approach performs gene selection using the weight vector
of the hyperplane constructed by the samples on the mar-
gin, i.e. support vectors. However, while this property may
be crucial for achieving good generalization performance,
the effect of using support vectors on gene selection
remains unclear, especially when it is applied to noisy,
small sample size microarray data. A recent work by Li and
Yang [10] implies that only penalizing redundant genes
for the samples on the margin may lead to poorer per-
formance.
In this paper, we propose a recursive gene selection
method based on the maximum margin criterion (MMC)
[11], which is a variant of classical linear discriminant
analysis (LDA). Guyon et al. [6] compared the perform-
ance between SVM-RFE and classical LDA-based RFE
(LDA-RFE), and claimed that the use of support vectors is
critical in eliminating irrelevant genes. However, the com-
parison is insufficient in the following respects:
• For computational reasons, LDA-RFE was performed by
eliminating half of genes at each iteration, whereas SVM-
RFE by eliminating one gene at a time.
￿ Cross-validation was performed improperly [12].
￿ The comparison was made only on a single dataset.
The computational drawback of classical LDA limits the
use of LDA-RFE for gene selection. This paper presents
efficient and stable algorithms for MMC-based RFE
(MMC-RFE), which overcomes the singularity problem of
classical LDA and the problem of high dimensionality. To
validate the effectiveness of MMC-RFE, we extensively
compare its performance with that of SVM-RFE using nine
cancer microarray datasets.
Results and discussion
Datasets
In this study, we used nine public datasets of cancer
microarrays. Five of the datasets concern binary-class pre-
diction problems: normal versus tumor for Colon cancer
[13] and Prostate cancer [14], ALL versus AML for Leuke-
mia [3], and clinical outcome for Medulloblastoma [15]
and Breast cancer [16]. Four of the datasets are on multi-
class subtype prediction problems: MLL [17], SRBCT [18],
CNS [15], and NCI60 [19]. The details of these datasets
are described below:
Colon cancer dataset [13]
This Affymetrix high-density oligonucleotide array dataset
contains 62 samples from 2 classes of colon-cancer
patients: 40 normal healthy samples and 22 tumor sam-
ples. The expression profiles of 2000 genes are used. The
dataset is publicly available at [20].
Prostate cancer dataset [14]
This Affymetrix high-density oligonucleotide array dataset
contains 102 samples from 2 classes: 50 normal tissue
samples and 52 prostate tumor samples. The expression
profiles of 12600 genes are used. The dataset is publicly
available at [21].
Leukemia dataset [3]
This Affymetrix high-density oligonucleotide array dataset
contains 38 samples from 2 classes of leukemia: 27 acute
lymphoblastic leukemia (ALL) and 11 acute myeloid
leukemia (AML). The expression profiles of 7129 genes
are used. The dataset is publicly available at [21]. Other 34
samples consisting of 20 ALL and 14 AML are used as an
independent test set as mentioned later.
Medulloblastoma dataset [15]
This Affymetrix high-density oligonucleotide array dataset
contains 60 samples from 2 classes on patient survivalBMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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with medulloblastoma: 21 treatment failures and 39 sur-
vivors. The expression profiles of 7129 genes are used. The
dataset is publicly available at [21].
Breast cancer dataset [16]
This cDNA microarray dataset contains 76 samples from 2
classes on five-year metastasis-free survival: 33 poor prog-
nosis and 43 good prognosis. The expression profiles of
4918 genes are used. The dataset is publicly available at
[22]. Other 19 samples with 12 poor prognosis and 7
good prognosis are used as an independent test set as
mentioned later.
MLL dataset [17]
This Affymetrix high-density oligonucleotide array dataset
contains 57 samples from 3 classes of leukemia: 20 acute
lymphoblastic leukemia (ALL), 17 mixed-lineage leuke-
mia (MLL), 20 acute myelogenous leukemia (AML). The
expression profiles of 12582 genes are used. The dataset is
publicly available at [21]. Note that a test dataset consist-
ing of 15 samples is not used here.
SRBCT dataset [18]
This cDNA microarray dataset contains 63 samples from 4
classes of small round blue-cell tumors of childhood
(SRBCT): 23 Ewing family of tumors, 20 rhabdomyosar-
coma, 12 neuroblastoma, and 8 non-Hodgkin lym-
phoma. The expression profiles of 2308 genes are used.
The dataset is publicly available at [23]. Note that a test
dataset consisting of 20 SRBCT and 5 non-SRBCT samples
is also available, but is not used here.
CNS dataset [15]
This Affymetrix high-density oligonucleotide array dataset
contains 42 samples from 5 different tumors of the central
nervous system (CNS): 10 medulloblastomas, 10 malig-
nant gliomas, 10 atypical teratoid/rhabdoid tumors, 8
primitive neuro-ectodermal tumors, and 4 human cere-
bella. The expression profiles of 7129 genes are used. The
dataset is publicly available at [21].
NCI60 dataset [19]
This cDNA microarray dataset contains 61 samples from 8
classes of human tumor cell lines: 9 breast, 5 CNS, 7
colon, 8 leukemia, 8 melanoma, 9 non-small cell lung car-
cinoma, 6 ovarian, and 9 renal tumors. The expression
profiles of 3938 genes are used. The dataset is publicly
available at [24].
Preprocessing
For the Prostate cancer, Leukemia, Medulloblastoma,
MLL, and CNS datasets, expression values were first
thresholded with a floor of 100 (10 for Prostate cancer)
and a ceiling of 16000, followed by a base 10 logarithmic
transform. Then, each sample was standardized to zero
mean and unit variance across genes. For the Colon cancer
dataset, after a base 10 logarithmic transform, each sam-
ple was standardized. For the Breast cancer dataset, after
the filtering of genes following [16], each sample was
standardized. For the NCI60 dataset, after filtering genes
with missing values, a base 2 logarithmic transform and
standardization were applied. For the SRBCT dataset, the
expression profiles already preprocessed following [18]
were used.
Gene selection methods for comparison
As a baseline gene selection criterion, we employed the
S2N ratio [4] for binary-class problems, and the BW ratio
[5] for multi-class problems. Top-ranked genes with the
largest ratios were used for classification. We primarily
compared two algorithms for MMC-RFE, called uncorre-
lated MMC-RFE and orthogonal MMC-RFE (see Meth-
ods), with SVM-RFE. For the SVM classifier, we used both
hard-margin SVM and soft-margin SVM with linear ker-
nel. The effect of using support vectors on gene selection
may be directly evaluated by hard-margin SVM, i.e. when
setting the soft-margin parameter C to infinity. The use of
soft-margin SVM can alleviate the influence of noise and
outliers to some extent and avoid overfitting of the data,
with the trade-off between training errors and the margin.
In the experiments, we used a wide range of values for the
C parameter: C = {0.001, 0.01, 0.1, 1, 10, 100, 1000}. The
extension of SVM to more than two classes is not obvious.
Hence, several approaches have been proposed for multi-
class SVMs, of which we employed one-versus-all SVM
(OVASVM). Ramaswamy et al. [25] showed the effective-
ness of the OVASVM approach for gene selection and clas-
sification, and Weston et al. [8] also applied it to gene
selection in multi-class problems. In this study, OVASVM-
based RFE was performed in the same way as in [8]. For
the implementation of SVM-RFE, we exploited the Spider
library for MATLAB, which is publicly available from [26].
Performance evaluation
We assessed the performance of each gene selection
method by repeated random splitting; the samples were
partitioned randomly in a class proportional manner into
a training set consisting of two-thirds of the whole sam-
ples and a test set consisting of the held-out one-third of
the samples. To avoid selection bias, gene selection was
performed using only the training set, and the classifica-
tion error rate of the learnt classifier was obtained using
the test set. This splitting was repeated 100 times. The
error rates averaged over the 100 trials and the corre-
sponding standard error rates are reported.
As a baseline classification method, we employed the
nearest mean classifier (NMC), which has been found
effective for cancer classification [27]. We combined each
gene selection method with NMC. Although the nearestBMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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neighbor classifier (NNC) was applied as well, NMC con-
sistently showed favorable performance compared with
NNC in the repeated random splitting experiments, and
thus the results on NMC are reported here. While the per-
formances of the gene selection methods can be com-
pared fair by using the same classifier, SVM-RFE is often
used as an integrated method of gene selection and classi-
fication, and MMC-RFE may also perform better when
used with the MMC classifier (see Methods). With this
view, we further compared the performance between
SVM-RFE in combination with the SVM classifier and
MMC-RFE with the MMC classifier. For multi-class data-
sets, the OVASVM classifier was used. 
As suggested by Weston et al. [8], to save computational
time of RFE, we removed half of the genes until less than
1000, and then a single gene at a time. In this study, we do
not address the problem of finding the optimum number
of genes that would yield highest classification accuracy.
Instead, the number of genes was varied from 1 to 100,
and the performances were compared for each number of
genes.
Performance comparison for binary-class datasets
Tables 1 and 2 show the average error and standard error
rates of each combination of classifiers and gene selection
criteria for the binary-class datasets: Colon cancer, Pros-
tate cancer, Leukemia, Medulloblastoma, and Breast can-
cer. Figures 1 and 2 plot the average error rates as a
function of the number of genes from 1 to 100. In the
tables and figures, MMC-RFE(U), MMC-RFE(O), SVM-
RFE(H) and SVM-RFE(S) stand for uncorrelated MMC-
RFE, orthogonal MMC-RFE, hard-margin SVM-RFE and
soft-margin SVM-RFE, respectively. For SVM-RFE(S), the
best result with respect to the C parameter is shown. Our
observations from these results are as follows:
￿ NMC+MMC-RFE(U,O) versus NMC+SVM-RFE(H,S) –
Overall, MMC-RFE(U,O) shows intermediate perform-
ance between SVM-RFE(H) and SVM-RFE(S) with the best
C parameter. MMC-RFE(O) is consistently better than
MMC-RFE(U), and notably MMC-RFE(O) performs the
best for Leukemia. In most cases, however, the difference
is not significant and they are quite competitive.
￿ MMC+MMC-RFE(U,O) versus SVM+SVM-RFE(H,S) –
The performance of MMC-RFE(U,O) is improved for Pros-
tate cancer. For the other datasets, the trend is similar to
the case of using NMC.
￿ S2N versus MMC-RFE(U,O), SVM-RFE(H,S) – Both
MMC-RFE(U,O) and SVM-RFE(H,S) improve the per-
formance of NMC over S2N for Prostate cancer, Leukemia
and Medulloblastoma. Wessels et al. [27] have reported
that NMC with S2N performs the best among various
combinations of gene selection methods and classifiers
for Colon cancer and Breast cancer. Consistently with
their results, S2N performs better than SVM-RFE(H) for
these datasets. However, a significant improvement is
achieved for SVM-RFE(S) by setting the C parameter to a
small value, e.g. 0.001. Huang and Kecman [28] also
reported that the finer tuning of the C parameter can sig-
nificantly improve the performance of SVM-RFE.
Guyon et al. [6] have drawn a conclusion from their result
on the Colon cancer dataset that SVM-RFE performs better
than both S2N and LDA-RFE. In their experiment, the C
parameter was set to 100. However, SVM-RFE(S) with C =
100 gives almost the same error rate as SVM-RFE(H) for all
the binary-class datasets in our study, and its performance
is poorer than that of S2N for Colon cancer, as mentioned
previously. There are some reasons that account for this
contradiction. First, although Guyon et al. [6] used SVM
and weighted voting [3] for classification, we have found
that for the Colon cancer dataset, SVM with C = 100 per-
forms significantly worse than NMC when combined with
S2N. As can be seen from Table 1, NMC+SVM-RFE(H)
performs even favorably against SVM+SVM-RFE(H). Sec-
ond, this can be attributed to the selection bias caused by
their improper use of cross-validation [12]; they failed to
include the gene selection process in the cross-validation.
Finally, the performance difference between LDA-RFE and
SVM-RFE may be due to the difference in the number of
genes eliminated at a time.
Guyon et al. [6] also compared the performance between
the mean squared error-based RFE (MSE-RFE) and SVM-
RFE, and claimed the superiority of SVM-RFE. However,
our results suggest that MSE-RFE might also show better
performance in some cases. Indeed, this has been implied
by the work of Li and Yang [10], which showed that ridge
regression-based RFE performed better than SVM-RFE. It
should be noted that MSE is closely related to classical
LDA and ridge regression [29,30]. MMC-RFE is still advan-
tageous over LDA-RFE and MSE-RFE, because MMC-RFE
does not need to compute the inverse of a matrix, which
makes MMC-RFE a computationally efficient and stable
method.
As our results indicate, the prediction of clinical outcome
is generally more difficult than that of tissue or disease
types. The error rates of NMC with S2N for the clinical
outcome datasets (Medulloblastoma and Breast Cancer)
almost coincide with the results presented in [31], which
performed a comparative study on outcome prediction
using the same validation strategy as our study. The result
for Medulloblastoma shows that the prediction perform-
ance can be improved by multivariate gene selection
methods such as MMC-RFE and SVM-RFE. However, it isBMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
Page 5 of 18
(page number not for citation purposes)
Table 1: Performance comparison for binary-class datasets.
Classifier+Selection 
criterion
Number of genes
10 20 30 50 100
Colon cancer
NMC+S2N 12.2 ± 0.6 12.5 ± 0.6 12.3 ± 0.6 12.8 ± 0.6 12.9 ± 0.5
NMC+MMC-RFE(U) 13.9 ± 0.6 12.5 ± 0.6 12.5 ± 0.6 12.1 ± 0.6 11.2 ± 0.5
NMC+MMC-RFE(O) 13.4 ± 0.6 11.7 ± 0.6 11.5 ± 0.6 11.3 ± 0.6 11.2 ± 0.6
NMC+SVM-RFE(H) 16.2 ± 0.7 14.6 ± 0.6 13.7 ± 0.6 12.5 ± 0.6 11.6 ± 0.6
NMC+SVM-RFE(S) 13.3 ± 0.6 11.2 ± 0.6 10.7 ± 0.5 10.5 ± 0.5 10.9 ± 0.5
MMC+MMC-RFE(U) 13.6 ± 0.6 12.1 ± 0.6 11.9 ± 0.6 11.7 ± 0.5 11.0 ± 0.5
MMC+MMC-RFE(O) 13.2 ± 0.6 11.7 ± 0.6 11.5 ± 0.6 11.0 ± 0.6 11.1 ± 0.6
SVM+SVM-RFE(H) 18.3 ± 0.6 16.2 ± 0.7 15.8 ± 0.7 15.0 ± 0.6 15.0 ± 0.6
SVM+SVM-RFE(S) 13.5 ± 0.5 10.7 ± 0.5 10.2 ± 0.5 10.0 ± 0.5 10.5 ± 0.6
Prostate cancer
NMC+S2N 10.1 ± 0.4 11.3 ± 0.5 12.3 ± 0.6 13.6 ± 0.6 16.0 ± 0.7
NMC+MMC-RFE(U) 9.9 ± 0.5 10.4 ± 0.5 10.8 ± 0.5 11.6 ± 0.5 13.4 ± 0.6
NMC+MMC-RFE(O) 9.6 ± 0.5 9.9 ± 0.5 10.3 ± 0.6 11.2 ± 0.6 13.5 ± 0.7
NMC+SVM-RFE(H) 9.6 ± 0.4 10.1 ± 0.5 10.2 ± 0.5 10.8 ± 0.5 12.2 ± 0.6
NMC+SVM-RFE(S) 9.7 ± 0.4 9.6 ± 0.4 10.0 ± 0.5 10.7 ± 0.5 12.4 ± 0.6
MMC+MMC-RFE(U) 8.8 ± 0.4 8.4 ± 0.4 8.4 ± 0.4 8.4 ± 0.4 8.6 ± 0.4
MMC+MMC-RFE(O) 8.5 ± 0.4 8.2 ± 0.4 7.9 ± 0.4 7.9 ± 0.4 8.1 ± 0.5
SVM+SVM-RFE(H) 9.9 ± 0.5 9.1 ± 0.4 9.3 ± 0.4 9.2 ± 0.4 9.1 ± 0.4
SVM+SVM-RFE(S) 8.5 ± 0.4 8.0 ± 0.4 8.5 ± 0.4 8.4 ± 0.4 8.8 ± 0.4
Leukemia
NMC+S2N 5.6 ± 0.7 5.8 ± 0.6 5.4 ± 0.6 3.8 ± 0.5 3.2 ± 0.5
NMC+MMC-RFE(U) 5.7 ± 0.6 3.9 ± 0.5 3.8 ± 0.5 2.2 ± 0.4 0.8 ± 0.2
NMC+MMC-RFE(O) 5.8 ± 0.6 2.8 ± 0.5 1.8 ± 0.4 0.8 ± 0.2 0.4 ± 0.2
NMC+SVM-RFE(H) 5.4 ± 0.6 3.8 ± 0.5 3.4 ± 0.5 1.8 ± 0.4 0.6 ± 0.2
NMC+SVM-RFE(S) 6.0 ± 0.6 3.1 ± 0.4 2.0 ± 0.4 1.5 ± 0.3 0.9 ± 0.3
MMC+MMC-RFE(U) 5.6 ± 0.6 3.7 ± 0.5 3.7 ± 0.5 2.3 ± 0.4 0.8 ± 0.3
MMC+MMC-RFE(O) 5.8 ± 0.6 2.8 ± 0.5 1.6 ± 0.3 0.6 ± 0.2 0.3 ± 0.2
SVM+SVM-RFE(H) 4.1 ± 0.5 3.0 ± 0.4 2.9 ± 0.4 1.3 ± 0.3 1.3 ± 0.3
SVM+SVM-RFE(S) 3.8 ± 0.5 3.1 ± 0.4 2.5 ± 0.4 1.3 ± 0.3 1.3 ± 0.3
The average error and standard error rates (%) for Colon cancer, Prostate cancer and Leukemia, when the number of genes is {10, 20, 30, 50, 100}. 
SVM-RFE(S) shows the best result with respect to the C parameter; NMC+SVM-RFE(S): C = 0.01, SVM+SVM-RFE(S): C = 0.01 for Colon cancer; 
NMC+SVM-RFE(S): C = 0.01, SVM+SVM-RFE(S): C = 0.01 for Prostate cancer; NMC+SVM-RFE(S): C = 0.001, SVM+SVM-RFE(S): C = 100 for 
Leukemia.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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at best an error rate of above 30% on average, when using
two-thirds of the samples as a training set.
Performance comparison for multi-class datasets
Tables 3 and 4 show the average error and standard error
rates of each combination of classifiers and gene selection
criteria for the multi-class datasets: MLL, SRBCT, CNS and
NCI60. Figures 3 and 4 plot the average error rates as a
function of the number of genes from 1 to 100. The
OVASVM approach was used here for SVM-RFE. We
observe from these results the following:
￿ NMC+MMC-RFE(U,O) versus NMC+SVM-RFE(H,S) –
MMC-RFE(U,O) outperforms SVM-RFE(H,S) for all the
datasets; it shows significantly better performance for a
smaller number of genes. MMC-RFE(U) appears to be bet-
ter than MMC-RFE(O) for SRBCT, while they are compa-
rable for the other datasets.
￿ MMC+MMC-RFE(U,O) versus SVM+SVM-RFE(H,S) –
The trend is similar to the case of using NMC. Although
the performance of NMC+SVM-RFE(H,S) is improved by
SVM+SVM-RFE(H,S) for SRBCT, it is still outperformed by
both NMC+MMC-RFE(U,O) and MMC+MMC-RFE(U,O).
￿ BW versus MMC-RFE(U,O), SVM-RFE(H,S) – MMC-
RFE(U,O) shows better performance than BW for three
datasets (MLL, SRBCT and NCI60), while performs com-
petitively with BW for CNS. In contrast, SVM-RFE(H,S)
performs even worse than BW for these datasets, which
suggests that OVASVM may not be suitable for selecting a
small number of discriminative genes.
Taken together, our extensive comparison has demon-
strated that for binary-class datasets MMC-RFE tends to
show intermediate performance between hard-margin
SVM-RFE and SVM-RFE with a properly chosen C param-
eter. Notably, MMC-RFE achieves significantly better per-
formance with a smaller number of genes than SVM-RFE
for multi-class datasets.
The results on hard-margin SVM-RFE indicate that the use
of support vectors is not necessarily effective for achieving
better performance in gene selection. Because the SVM-
Table 2: Performance comparison for binary-class datasets (continued).
Classifier+Selection 
criterion
Number of genes
10 20 30 50 100
Medulloblastoma
NMC+S2N 42.1 ± 1.1 40.9 ± 1.0 40.1 ± 0.9 40.8 ± 1.0 39.3 ± 1.1
NMC+MMC-RFE(U) 39.0 ± 1.0 36.5 ± 1.1 36.5 ± 1.0 35.8 ± 0.9 35.2 ± 1.0
NMC+MMC-RFE(O) 39.7 ± 0.9 37.1 ± 0.9 34.7 ± 0.9 33.2 ± 0.9 32.4 ± 0.9
NMC+SVM-RFE(H) 42.2 ± 1.1 38.5 ± 1.0 37.5 ± 1.0 34.8 ± 0.9 34.3 ± 0.9
NMC+SVM-RFE(S) 35.3 ± 0.9 32.8 ± 0.9 32.3 ± 0.9 31.5 ± 0.9 31.0 ± 0.9
MMC+MMC-RFE(U) 38.8 ± 0.9 36.9 ± 1.0 36.4 ± 1.0 35.8 ± 0.9 35.3 ± 1.0
MMC+MMC-RFE(O) 40.0 ± 0.9 37.0 ± 0.9 34.0 ± 0.9 32.9 ± 0.9 32.2 ± 0.9
SVM+SVM-RFE(H) 41.0 ± 1.0 37.9 ± 0.9 36.8 ± 0.9 35.7 ± 0.9 36.0 ± 0.9
SVM+SVM-RFE(S) 34.6 ± 0.4 32.9 ± 0.6 33.2 ± 0.8 33.9 ± 0.8 34.6 ± 0.8
Breast cancer
NMC+S2N 34.2 ± 0.8 34.5 ± 0.8 35.0 ± 0.8 35.9 ± 0.8 36.1 ± 0.8
NMC+MMC-RFE(U) 38.0 ± 0.8 37.3 ± 0.7 36.8 ± 0.8 36.7 ± 0.7 35.4 ± 0.7
NMC+MMC-RFE(O) 37.7 ± 0.7 36.4 ± 0.7 35.6 ± 0.7 34.8 ± 0.7 35.2 ± 0.7
NMC+SVM-RFE(H) 39.4 ± 0.8 37.8 ± 0.7 36.6 ± 0.8 36.5 ± 0.7 35.6 ± 0.7
NMC+SVM-RFE(S) 36.6 ± 0.9 34.4 ± 0.8 34.1 ± 0.7 33.8 ± 0.7 33.4 ± 0.7
MMC+MMC-RFE(U) 38.5 ± 0.9 39.3 ± 0.7 38.2 ± 0.7 38.4 ± 0.7 37.2 ± 0.8
MMC+MMC-RFE(O) 38.0 ± 0.8 38.2 ± 0.8 37.0 ± 0.7 38.0 ± 0.7 36.9 ± 0.7
SVM+SVM-RFE(H) 41.1 ± 1.0 41.3 ± 0.9 41.7 ± 1.0 40.8 ± 0.8 40.7 ± 0.8
SVM+SVM-RFE(S) 43.4 ± 0.3 38.2 ± 0.6 36.3 ± 0.7 34.8 ± 0.7 35.0 ± 0.7
The average error and standard error rates (%) for Medulloblastoma and Breast cancer, when the number of genes is {10, 20, 30, 50, 100}. SVM-
RFE(S) shows the best result with respect to the C parameter; NMC+SVM-RFE(S): C = 0.001, SVM+SVM-RFE(S): C = 0.01 for Medulloblastoma; 
NMC+SVM-RFE(S): C = 0.001, SVM+SVM-RFE(S): C = 0.001 for Breast cancer.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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based approach to gene selection uses the weight vector of
the hyperplane constructed by the training samples clos-
est to the decision boundary, the performance can be eas-
ily affected by noise and possible outliers. As the results
on the binary-class datasets show, SVM-RFE can achieve a
significant improvement for some of the datasets by set-
ting the C parameter to a small value. The soft-margin
parameter plays more roles than just handling noisy data;
it is effective for linearly inseparable cases and crucial for
avoiding overfitting.
In contrast, MMC-RFE uses the discriminant vector
obtained by maximizing the average margin, hence less
sensitive to noise and outliers. In addition, no parameters
need to be tuned. Although MMC-RFE may not be so flex-
ible as soft-margin SVM-RFE, orthogonal MMC-RFE
shows comparable performance to SVM-RFE with the best
C parameter for some cases. Another advantage of MMC-
RFE is that it naturally extends to multi-class cases, while
the SVM-based approach typically treats them by decom-
posing the multi-class problems into many binary-class
ones, e.g. one-versus-one and one-versus-all strategies.
Therefore, MMC-RFE is in particular effective for gene
selection in multi-class problems, which has also been
validated by the performance on the multi-class datasets.
Comparison of selected genes
It is clearly of interest to compare the selected genes of
MMC-RFE with those of S2N and SVM-RFE. To this end,
we conducted additional experiments using independent
test sets. The results were obtained for the Prostate cancer,
Leukemia, and Breast cancer datasets. Note that the test set
for Prostate cancer is from [32], which is available at [33].
It contains 25 normal tissue samples and 9 prostate tumor
samples. Gene selection was performed using the whole
samples in the previous experiment, and the classification
error rate of the learnt classifier was obtained using the
independent test set. NNC and NMC were used here for
Performance comparison for binary-class datasets Figure 1
Performance comparison for binary-class datasets. The average error rates (%) as a function of the number of genes 
from 1 to 100, for Colon cancer, Prostate cancer and Leukemia.
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Performance comparison for binary-class datasets (continued) Figure 2
Performance comparison for binary-class datasets (continued). The average error rates (%) as a function of the 
number of genes from 1 to 100, for Medulloblastoma and Breast cancer.
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classification, and the number of genes was varied from 1
to 100.
For each dataset, the minimum number of misclassifica-
tions as well as the number of genes used are shown in
Table 5. Both uncorrelated MMC-RFE and orthogonal
MMC-RFE achieve zero misclassifications using a small
number of genes for Prostate cancer and Leukemia,
although S2N and SVM-RFE also perform comparably
well. While S2N and MMC-RFE misclassify three or four
test samples for Breast cancer, SVM-RFE yields fewer mis-
classifications with NMC by using C = 0.001.
Tables 6, 7, 8 list the 10 top-ranked genes of orthogonal
MMC-RFE and the corresponding ranks by S2N and SVM-
RFE. Note that the lists of uncorrelated MMC-RFE are sim-
ilar to those of orthogonal MMC-RFE, and hence omitted.
For Prostate cancer, 7 genes are included in the list of 16
genes identified by Singh et al. [14] (Table 6). Of note,
HPN (X07732) is ranked the first by all the three gene
selection methods. It is known that hepsin, a cell surface
serine protease, is overexpressed in prostate cancer and
has been identified as a potential prostate-cancer biomar-
ker [32,34-36]. HPN  and  CFD  (M84526) are the two
genes that are selected by uncorrelated MMC-RFE and
achieve perfect classification with NMC. We can see that
some of these genes are also highly ranked by S2N and
SVM-RFE. Despite that there are differences in the pre-
processing steps and gene selection criteria used, half the
genes are included in the lists of the original studies for
Leukemia and Breast cancer (Tables 7 and 8); the number
of genes identified and used for prediction was 50 for
Leukemia [3] and 70 for Breast cancer [16], respectively. It
appears that the top-ranked genes of orthogonal MMC-
RFE show a larger overlap with those of SVM-RFE than
with those of S2N. Indeed, almost all the listed genes
belong to the 50 top-ranked genes of SVM-RFE. On the
other hand, some of them are assigned small ratio values
Table 3: Performance comparison for multi-class datasets.
Classifier+Selection 
criterion
Number of genes
10 20 30 50 100
MLL
NMC+BW 11.5 ± 0.7 8.8 ± 0.6 7.4 ± 0.5 6.1 ± 0.5 5.6 ± 0.5
NMC+MMC-RFE(U) 7.0 ± 0.6 5.8 ± 0.5 5.1 ± 0.5 4.9 ± 0.5 4.0 ± 0.4
NMC+MMC-RFE(O) 6.4 ± 0.5 5.9 ± 0.5 5.6 ± 0.5 4.9 ± 0.4 4.4 ± 0.4
NMC+SVM-RFE(H) 26.9 ± 1.4 19.3 ± 1.2 15.5 ± 1.1 12.0 ± 0.8 9.1 ± 0.7
NMC+SVM-RFE(S) 28.0 ± 1.3 21.4 ± 1.1 16.6 ± 1.0 11.9 ± 0.8 7.9 ± 0.7
MMC+MMC-RFE(U) 6.8 ± 0.5 6.0 ± 0.5 5.2 ± 0.5 4.9 ± 0.5 4.0 ± 0.4
MMC+MMC-RFE(O) 6.4 ± 0.5 5.8 ± 0.5 5.6 ± 0.5 4.9 ± 0.4 4.5 ± 0.4
SVM+SVM-RFE(H) 31.3 ± 1.5 24.0 ± 1.4 18.3 ± 1.1 12.9 ± 0.8 7.9 ± 0.6
SVM+SVM-RFE(S) 26.2 ± 1.2 20.2 ± 1.1 14.4 ± 1.0 10.6 ± 0.8 6.8 ± 0.6
SRBCT
NMC+BW 35.2 ± 1.4 22.1 ± 0.7 19.3 ± 0.7 10.5 ± 0.7 7.6 ± 0.6
NMC+MMC-RFE(U) 5.0 ± 0.5 3.0 ± 0.4 2.4 ± 0.3 2.2 ± 0.3 2.7 ± 0.3
NMC+MMC-RFE(O) 8.9 ± 0.7 6.0 ± 0.5 6.5 ± 0.5 6.8 ± 0.5 6.4 ± 0.5
NMC+SVM-RFE(H) 29.2 ± 1.2 22.9 ± 1.1 19.5 ± 1.0 15.7 ± 0.9 11.6 ± 0.7
NMC+SVM-RFE(S) 27.2 ± 1.2 21.9 ± 1.2 18.3 ± 1.0 14.2 ± 0.7 11.1 ± 0.8
MMC+MMC-RFE(U) 4.4 ± 0.5 2.5 ± 0.3 2.0 ± 0.3 1.7 ± 0.3 1.3 ± 0.2
MMC+MMC-RFE(O) 4.7 ± 0.5 4.1 ± 0.4 4.4 ± 0.4 3.5 ± 0.4 3.3 ± 0.4
SVM+SVM-RFE(H) 24.0 ± 1.3 14.2 ± 1.0 9.6 ± 0.7 6.3 ± 0.5 3.6 ± 0.4
SVM+SVM-RFE(S) 24.8 ± 1.4 12.7 ± 1.1 8.8 ± 0.8 5.1 ± 0.5 3.4 ± 0.4
The average error and standard error rates (%) for MLL and SRBCT, when the number of genes is {10, 20, 30, 50, 100}. SVM-RFE(S) shows the best 
result with respect to the C parameter; NMC+SVM-RFE(S): C = 0.1, SVM+SVM-RFE(S): C = 0.1 for MLL; NMC+SVM-RFE(S): C = 100, SVM+SVM-
RFE(S): C = 1000 for SRBCT.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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by S2N. This may be due to the difference in gene selec-
tion approaches; MMC-RFE and SVM-RFE are multivari-
ate, whereas S2N is univariate. It is interesting to note that
the first rank gene of SVM-RFE for Breast cancer is PRAME
(NM_006115), which in combination with TSPYL5
(AL080059) yields only one misclassification with NMC.
The rank of PRAME by orthogonal MMC-RFE and S2N is
33 and 107, respectively. Overall, these results show that
MMC-RFE can identify a small subset of discriminative
genes that is quite consistent with previous studies.
Conclusion
In this paper, we have proposed a recursive gene selection
method based on the MMC, and presented efficient and
stable algorithms for MMC-RFE. The performance of
MMC-RFE was extensively compared with that of SVM-
RFE using nine cancer microarray datasets, including four
multi-class datasets. We further compared the top-ranked
genes selected by MMC-RFE with those of other gene
selection methods, showing the validity of MMC-RFE.
The results suggest that MMC-RFE is less sensitive to noise
and outliers due to the use of average margin, while the
performance of SVM-RFE can be easily affected by them
when applied to noisy, small sample size microarray data.
Another advantage of MMC-RFE over SVM-RFE is that
MMC-RFE naturally extends to multi-class cases. Further-
more, MMC-RFE does not require the computation of the
matrix inversion unlike LDA-RFE and MSE-RFE, and
involves no parameters to be tuned.
This study has shown the effectiveness of the MMC for
gene selection using microarray data. Our proposed algo-
rithms can also be applied to proteomics and metabo-
lomics datasets, and may be useful for biomarker
discovery from such noisy data.
Methods
Maximum margin criterion
Linear discriminant analysis (LDA) aims to find a set of
projection vectors which maximize the between-class scat-
Table 4: Performance comparison for multi-class datasets (continued).
Classifier+Selection 
criterion
Number of genes
10 20 30 50 100
CNS
NMC+BW 31.1 ± 1.3 23.1 ± 1.2 20.1 ± 1.1 18.3 ± 1.0 15.9 ± 1.0
NMC+MMC-RFE(U) 27.2 ± 1.1 22.8 ± 0.9 21.9 ± 0.9 19.4 ± 0.8 16.8 ± 0.8
NMC+MMC-RFE(O) 24.4 ± 1.0 22.7 ± 0.8 22.1 ± 0.9 20.6 ± 0.9 18.9 ± 0.8
NMC+SVM-RFE(H) 45.6 ± 1.3 35.4 ± 1.0 33.3 ± 1.0 28.8 ± 0.9 24.9 ± 0.8
NMC+SVM-RFE(S) 45.4 ± 1.3 34.9 ± 1.0 32.5 ± 0.9 27.6 ± 0.8 24.6 ± 0.8
MMC+MMC-RFE(U) 27.6 ± 1.1 22.5 ± 0.9 21.3 ± 0.9 19.2 ± 0.8 16.9 ± 0.8
MMC+MMC-RFE(O) 24.4 ± 1.0 22.9 ± 0.8 22.2 ± 0.9 20.2 ± 0.9 19.4 ± 0.8
SVM+SVM-RFE(H) 54.0 ± 1.5 42.6 ± 1.4 36.8 ± 1.3 31.0 ± 0.9 25.2 ± 0.8
SVM+SVM-RFE(S) 47.3 ± 1.2 37.7 ± 1.1 32.6 ± 1.1 28.4 ± 1.0 26.6 ± 0.9
NCI60
NMC+BW 49.8 ± 1.2 44.0 ± 1.0 41.6 ± 1.0 39.1 ± 0.8 37.7 ± 0.7
NMC+MMC-RFE(U) 46.4 ± 0.8 38.9 ± 0.8 34.0 ± 0.9 29.8 ± 0.9 26.8 ± 0.7
NMC+MMC-RFE(O) 48.2 ± 0.9 39.6 ± 0.9 35.0 ± 0.9 31.6 ± 0.8 30.2 ± 0.9
NMC+SVM-RFE(H) 60.6 ± 1.0 51.4 ± 1.0 48.4 ± 1.0 43.4 ± 0.9 38.0 ± 0.8
NMC+SVM-RFE(S) 60.8 ± 1.0 52.2 ± 0.9 47.3 ± 1.0 41.3 ± 0.9 39.0 ± 0.9
MMC+MMC-RFE(U) 46.0 ± 0.9 37.3 ± 0.8 33.7 ± 0.8 29.0 ± 0.9 25.0 ± 0.7
MMC+MMC-RFE(O) 49.0 ± 1.0 38.6 ± 0.9 34.3 ± 0.9 30.4 ± 0.8 28.7 ± 0.9
SVM+SVM-RFE(H) 64.7 ± 1.2 54.3 ± 1.1 47.7 ± 1.0 42.0 ± 0.9 35.9 ± 0.9
SVM+SVM-RFE(S) 59.9 ± 1.1 50.3 ± 1.0 46.2 ± 1.0 42.8 ± 1.1 35.8 ± 0.9
The average error and standard error rates (%) for CNS and NCI60, when the number of genes is {10, 20, 30, 50, 100}. SVM-RFE(S) shows the best 
result with respect to the C parameter; NMC+SVM-RFE(S): C = 10, SVM+SVM-RFE(S): C = 0.1 for CNS; NMC+SVM-RFE(S): C = 100, SVM+SVM-
RFE(S): C = 0.1 for NCI60.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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Performance comparison for multi-class datasets Figure 3
Performance comparison for multi-class datasets. The average error rates (%) as a function of the number of genes 
from 1 to 100, for MLL and SRBCT.
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Performance comparison for multi-class datasets (continued) Figure 4
Performance comparison for multi-class datasets (continued). The average error rates (%) as a function of the 
number of genes from 1 to 100, for CNS and NCI60.
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Table 5: Performance comparison for independent test samples.
Dataset Classifier # misclassifications (# genes)
S2N MMC-RFE(U) MMC-RFE(O) SVM-RFE
Prostate cancer NNC 1 (1) 0 (45) 0 (22) 1 (1)
NMC 1 (1) 0 (2) 0 (22) 1 (1)
Leukemia NNC 0 (50) 0 (3) 0 (3) 0 (3)
NMC 1 (15) 0 (54) 0 (29) 1 (1)
Breast cancer NNC 4 (19) 3 (91) 3 (85) 4 (2)
NMC 4 (1) 4 (35) 4 (36) 1 (2)
Minimum number of misclassifications and the number of genes used for Prostate cancer, Leukemia and Breast cancer. The C parameter of SVM-
RFE was set to 0.01 for Prostate cancer, and to 0.001 for Leukemia and Breast cancer.
Table 6: Comparison of selected genes for Prostate cancer.
Rank GAN [14] Rank Gene description
S2N SVM-RFE
1 X07732 • 1 1 hepsin (transmembrane protease, serine 1) (HPN)
2 M30894 • 2 2 TCR gamma alternate reading frame protein (TARP)
3 M84526 • 3 89 complement factor D (adipsin) (CFD)
4 AL049969 • 4 65 PDZ and LIM domain 5 (PDLIM5)
5 X51345 38 5 jun B proto-oncogene (JUNB)
6 U21689 68 6 glutathione S-transferase pi (GSTP1)
7 M98539 • 297 15 prostaglandin D2 synthase 21kDa (brain) (PTGDS)
8 X17206 95 12 ribosomal protein S2 (RPS2)
9 D83018 • 6 41 NEL-like 2 (chicken) (NELL2)
10 AF065388 • 18 13 tetraspanin 1 (TSPAN1)
The 10 top-ranked genes of orthogonal MMC-RFE are listed in order of the rank; GAN: Gene Accession Number. Genes selected by Singh et al. 
[14] are denoted by •. C = 0.01 was used for SVM-RFE.
Table 7: Comparison of selected genes for Leukemia.
Rank GAN [3] Rank Gene description
S2N SVM-RFE
1 M27891 • 1 2 cystatin C (CST3)
2 M28130 • 25 3 interleukin 8 (IL8)
3 M84526 • 5 1 D component of complement (adipsin) (DF)
4 M19507 131 7 myeloperoxidase (MPO)
5 Y00787 • 23 4 interleukin-8 precursor
6 M11722 71 41 deoxynucleotidyltransferase, terminal (DNTT)
7 X95735 • 2 11 zyxin (ZYX)
8 D88422 3 8 cystatin A (CSTA)
9 M27783 15 5 elastase 2, neutrophil (ELA2)
10 M96326 • 75 10 azurocidin 1 (AZU1)
The 10 top-ranked genes of orthogonal MMC-RFE are listed in order of the rank; GAN: Gene Accession Number. Genes selected by Golub et al. 
[3] are denoted by •. C = 0.001 was used for SVM-RFE.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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ter and simultaneously minimize the within-class scatter,
thereby achieving maximum discrimination [37].
The between-class scatter matrix Sb and the within-class
scatter matrix Sw are defined as
where c is the number of classes, mi and pi are the mean
and a priori probability of class i, m is the total mean, and
Si is the covariance matrix of class i. Then, classical LDA
finds the projection vectors W by maximizing the Fisher
criterion
J (W) = trace ((WT Sw W)-1 (WT Sb W)).   (1)
By solving a generalized eigenvalue problem, the projec-
tion vectors W can be found as the eigenvectors of  Sb
corresponding to the largest eigenvalues. When the sam-
ple size is smaller than the dimensionality of samples,
however, Sw becomes singular and we cannot compute
Sb, which is a major drawback of classical LDA.
To overcome the singularity problem, several methods
have been proposed e.g. in the field of computer vision,
where the number of samples is usually much smaller
than the dimensionality. A simple approach is to replace
 with the pseudo-inverse matrix  . Another
approach is to add some constant values to the diagonal
elements of Sw as Sw + μI, where μ > 0 and I is the identity
matrix. However, each of these methods has its own draw-
backs and does not scale well to high-dimensional data
(see [11] for more details). Recently, Li et al. [11] pro-
posed to use the maximum margin criterion (MMC)
instead of (1) to find the projection vectors. The MMC is
defined as
J (W) = trace (WT (Sb - Sw) W)).   (2)
The projection vectors W = (w1,..., wd) which maximize
(2) under the constraint that  wk = 1, k = 1,..., d, can be
found as the eigenvectors of Sb - Sw corresponding to the
largest eigenvalues. The advantage of using the MMC is
that we need not compute the inverse of Sw, hence the sin-
gularity problem can be easily avoided.
It is known that classical LDA can be related to SVM.
Shashua [38] has shown that, in binary-class cases, the
orientation and location of the hyperplane obtained by
SVM is equivalent to the discriminant vector obtained by
classical LDA using the samples on the margin. In other
words, SVM can be viewed as sparsified LDA. Thus, noting
that the MMC is different from classical LDA only in its
constraint [11], the major difference between SVM and
the MMC consists in that the hyperplane of SVM is con-
structed only by the training samples closest to the deci-
sion boundary, while the discriminant vector of the MMC
is constructed so that the average margin computed by all
training samples is maximized. They also lead to different
problems to solve: a quadratic programming problem for
the standard L2 SVM and an eigenvalue problem for the
MMC. Note that for L1 SVM, it can be reduced to a linear
programming problem (see [9] and references therein).
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Table 8: Comparison of selected genes for Breast cancer.
Rank GAN [16] Rank Gene description
S2N SVM-RFE
1 Contig63649_RC • 3 40 ESTs
2 AL080059 • 1 2 TSPY-like5 (TSPYL5)
3 Contig27312_RC 133 48 collagen, type XXIII, alpha 1 (COL23A1)
4 NM_001756 412 35 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 (SERPINA6)
5 Contig48328_RC • 2 4 zinc finger protein 533 (ZNF533)
6 NM_001635 69 24 amphiphysin (AMPH)
7 NM_006681 • 17 13 neuromedin U (NMU)
8 NC_001807 1174 39 Human mitochondrion (ND1)
9 NM_000599 • 53 38 insulin-like growth factor binding protein 5 (IGFBP5)
10 NM_000518 1387 45 hemoglobin, beta (HBB)
The 10 top-ranked genes of orthogonal MMC-RFE are listed in order of the rank; GAN: Gene Accession Number. Genes selected by van't Veer et 
al. [16] are denoted by •. C = 0.001 was used for SVM-RFE.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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MMC-RFE algorithms for gene selection
The idea of recursive feature elimination (RFE) [6] is to
recursively remove genes using the absolute weights of the
discriminant vector or hyperplane, which reflect the sig-
nificance of the genes for classification. The process starts
by training the classifier using all genes. Then, the genes
are ranked according to the absolute weights, and those
genes with the smallest absolute weights are removed. The
classifier is retrained with the remaining genes. This proc-
ess is repeated until the maximum classification accuracy
is obtained or the number of genes reaches a predeter-
mined value. The RFE approach has recently been shown
to be effective not only with SVM but also with penalized
logistic regression [39] and ridge regression [10].
Here, we propose a recursive gene selection method based
on the MMC. The MMC is computationally more efficient
and stable than classical LDA, yet it does not scale well to
high-dimensional data. When we consider using RFE with
the MMC, it is computationally intensive to perform the
eigenvalue decomposition (EVD) of the matrix of the
gene size in a recursive manner. To overcome the problem
of high dimensionality, we first remove the null space of
the total scatter matrix via singular value decomposition
(SVD) [40], thereby reduce the dimensionality of the data
to n - 1, where n is the number of samples, and then max-
imize the MMC in the reduced space. Let X denote the
gene expression matrix of size p × n, where p is the number
of genes. Then, the total scatter matrix St can be expressed
as
where
and e  = (1,1,..., 1)T is an n-dimensional vector. Let us
assume that p > n and perform the reduced SVD of   as
where   =  diag (λ1,..., λn) with decreasing non-negative
values, and   and   are p × n and n × n orthonormal
matrices. Since the rank of St is n - 1, i.e. λn = 0, we can
rewrite (3) as
 = UΛVT,
where Λ = diag (λ1,..., λn - 1), and U and V are p × (n - 1)
and n × (n - 1) matrices consisting of the corresponding (n
- 1) vectors. Thus, we can reduce the dimension by pro-
jecting X onto the (n - l)-dimensional space as
Z = Λ-1 UT X.   (4)
Then, we may maximize the MMC on Z, which is a (n - 1)
× n matrix. Here, we require W to be orthogonal, i.e. WT
W = I, in the reduced space. Once the discriminant vectors
W of size (n - 1) × d is obtained, they are projected back
onto the original p-dimensional space by
 = U Λ-1 W,   (5)
where   is of size p × d. Finally, gene selection can be
performed using  . When using (4), we can show that
the number of the discriminant vectors that correspond to
the positive eigenvalues is at most c - 1. Because the eigen-
values reflect the discrimination ability, we use the (c - 1)
discriminant vectors corresponding to the positive eigen-
values, i.e. d is set to c - 1, and discard those corresponding
to the negative eigenvalues.
Li et al. [11] proposed another efficient method to com-
pute the projection vectors of the MMC. It is interesting to
note that the MMC is related to uncorrelated LDA
(ULDA), and we can find that the Li's method is the same
as the ULDA algorithm proposed by Ye [41]. It can be
shown that   in (5) maximizes the MMC on X under the
constraint that  T St   = I, and our method turns out to
be equivalent to the ULDA algorithm. Hence, we call the
algorithm based on (4) uncorrelated MMC-RFE. 
This study also explores the following projection instead
of (4):
Z = UT X.   (6)
After obtaining the discriminant vectors W by maximizing
the MMC on Z, they are projected back onto the original
p-dimensional space by
 = U W.   (7)
Note that no discriminant information is lost in the case
of (6) [42]. It can be shown that   in (7) maximizes the
MMC on X under the constraint that  T   = I. We call
the algorithm based on (6) orthogonal MMC-RFE. We see
that the difference between (4) and (6) results in the dif-
ferent constraints of the MMC on X.
SX X t
T =  ,
 XX m e =−
1
n
T () ,
 X
   XU V = Λ Λ T             (3),
 Λ Λ
 U  V
 X
 W
 W
 W
 W
 W  W
 W
 W
 W  WBMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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The uncorrelated MMC-RFE and orthogonal MMC-RFE
algorithms are summarized in Figures 5 and 6, respec-
tively. They are different in step 3 and step 6. The main
computation of both algorithms consists of the SVD of a
p × n matrix at step 2 and the EVD of a (n - 1) × (n - 1)
matrix at step 5. Thus, the algorithms are feasible in the
case of high dimensionality and small sample size, i.e.
large p and small n. As is shown, the MMC-RFE algorithms
can naturally treat multi-class cases, in which the weight
of gene j can be defined as the sum of the absolute weights
of c - 1 discriminant vectors in  , i.e.  . The
maximum of the absolute weights, i.e. maxk = 1,..., c - 1 | jk|,
may also be useful. Note that the uncorrelated MMC-RFE
algorithm switches to orthogonal MMC-RFE at q = n - 1,
where q is the number of remaining genes during elimina-
tion. Hence, our algorithm and the ULDA algorithm may
select different genes when q ≤ n - 1.
MMC classifier
The MMC classifier performs nearest mean classification
in the projected space, i.e. the class label y of a test sample
x is predicted as
where mi is the mean of class i. Since we perform classifi-
cation using at most 100 genes in the experiments, the dis-
criminant vectors W  were computed by directly
maximizing the MMC under the orthogonality constraint.
S2N ratio and BW ratio
For each gene j, the S2N ratio [4] is defined as
where  ,   and  ,   denote the means and
standard deviations of two classes, respectively. Top-
ranked genes are those with the largest values of S2N(j).
The BW ratio [5] can be defined as
where   and   respectively denote the average
expression level of gene j for class k and the overall average
expression level of gene j across all samples, yi denotes the
class of sample i, and I (·) is the indicator function. Top-
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The uncorrelated MMC-RFE algorithm Figure 5
The uncorrelated MMC-RFE algorithm.BMC Bioinformatics 2006, 7:543 http://www.biomedcentral.com/1471-2105/7/543
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ranked genes with the largest values of BW(j) are used for
classification.
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